Navigation Links
Effort aims to spike breast cancer with new approach
Date:3/11/2010

SCOTTSDALE, Ariz. March 11, 2010 Many women live with breast cancer that does not respond to standard medical treatment, a condition that researchers at the Virginia G. Piper Cancer Center at Scottsdale Healthcare want to change by aggressively targeting specific genes.

Improving quality of life and potentially keeping the cancer under control for a longer period of time are goals of a new clinical trial at the cancer center's TGen Clinical Research Services, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

The pilot study is supported by the Side-Out Foundation, a group founded by volleyball enthusiasts to help wage war on breast cancer.

Women or men with advanced breast cancer that has progressed through three prior treatments are eligible for the trial, available in the western U.S. only at Scottsdale Healthcare's Virginia G. Piper Cancer Center.

"Many are living with refractory, or advanced, breast cancer that has not responded or continues to grow despite standard treatments," explains Nurse Practitioner Gayle Jameson, principal investigator. "What we are offering here is a whole new approach for treating patients with refractory breast cancer."

Biopsied tissue will be analyzed for unique characteristics and abnormal genes in cancer cells, which are then targeted for treatment with FDA-approved anticancer medications. "We may discover that a tumor has a gene mutation that responds to a drug not typically used in a 'one-size-fits-all' approach," explains Jameson.

"What we are doing here is precisely matching a treatment to a specific type of cancer cell mutation and abnormal protein signaling pathways that may activate cancer cell growth. The patient would then be treated with one or more medications based on the information provided by the analyses."

Researchers call the Side-Out study the "next generation of breast cancer treatment," expanding on what was learned about molecular profiling in an earlier clinical trial at the Virginia G. Piper Cancer Center. The new study, managed by TGen Drug Development (TD2), is open to a total of 25 patients at only two sites, the Virginia G. Piper Cancer Center at Scottsdale Healthcare and Fairfax Northern Virginia Hematology Oncology.

Results of the earlier trial, known as the Bisgrove Study, showed that molecular profiling can identify specific treatments that help keep cancer in check for significantly longer periods, and in some cases even shrinking tumors. Clinical trials at the cancer center are administered by the Scottsdale Healthcare Research Institute.

Research at the Virginia G. Piper Cancer Center at Scottsdale Healthcare allows molecular and genomic discoveries to reach the patient bedside as quickly as possible through clinical trials of therapies directed at specific targets in patients' tumors.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts
2. New Alzheimers Prevention Efforts, and Non-Drug Treatments, Featured at 25th Conference of Alzheimers Disease International
3. Having Prediabetes May Not Kick-Start Prevention Efforts
4. California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort
5. Buildium Announces Fundraising Campaign to Benefit Haiti Relief Efforts
6. ChildCare Education Institute Supports the First Ladys Efforts to Reduce Childhood Obesity
7. JPMA Supports CPSC Chairman Tenenbaum's Continued Safety Efforts
8. Lighthouse To Help Relief Efforts In Haiti
9. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
10. Reliv Foundation Donates $450,000 In Nutritional Supplements to Haitian Relief Efforts
11. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... Data Integrity: , The Key to FDA ... 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity , Consider this situation. ... electronic records may not be trustworthy and reliable … a more detailed evaluation may ...
(Date:9/26/2017)... Milford, PA (PRWEB) , ... September 26, 2017 , ... ... month in Chicago, called “The Magic of Fat,” revealed not only the latest about ... might prove to be an evolution in cosmetic medicine. , “Fat really is magical, ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding ... and overcoming obstacles. “Good Morning Sunshine!: Finding Strength and Comfort in God” is the ... psychology from Fort Hays Sate University, who has worked at a local mental health ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sonflower Submission”: a ... nature to the inevitable destinations of negativity, complaining and the need to always be ... take effect in order for a lesson in stress-less living to be learned. ...
(Date:9/26/2017)... ... ... out for Daddy is a moving story of a family's unconditional love for each ... for Daddy” is the creation of published author Debra Titus, who has lived in ... her to write this book. , Published by Christian Faith Publishing, Debra Titus’s new ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... company focused on the development of oral drug delivery ... meeting with the U.S. Food and Drug Administration (FDA) ... At the meeting, the ... submission of ORMD-0801, would be a Biologics License Application ...
Breaking Medicine Technology: